Condensed Statements of Cash Flows - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Cash flows from operating activities
Net loss	$ (14,873)	$ (11,307)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation	16	14
Stock-based compensation expense	2,484	1,390
Amortization of premiums and accretion of discounts on marketable securities, net	(1,763)	(334)
Change in fair value of embedded derivatives	50	0
Amortization of right-of-use asset	28	38
Realized gain on marketable securities	(2)	0
Non-cash interest expense	268	0
Changes in operating assets and liabilities:
Prepaid expenses and other current assets	(226)	(899)
Other assets	35	(44)
Accounts payable	1,700	(878)
Accrued clinical trial expenses	(2,020)	2,486
Accrued expenses and other current liabilities	(3,512)	(603)
Finance lease liability	(23)	0
Operating lease liability	(21)	(38)
Net cash used in operating activities	(17,859)	(10,175)
Cash flows from investing activities
Purchases of marketable securities	(45,292)	(52,131)
Proceeds from maturities and sales of marketable securities	36,100	10,204
Purchases of property and equipment	(11)	0
Net cash used in investing activities	(9,203)	(41,927)
Cash flows from financing activities
Proceeds from issuance of common stock, net of issuance costs	7,938	0
Payment for financing lease	(739)	0
Payments for deferred offering costs	(60)	0
Repurchase of common shares to pay employee withholding taxes	(32)	0
Net cash provided by financing activities	7,107	0
Net change in cash and cash equivalents and restricted cash	(19,955)	(52,102)
Cash and cash equivalents and restricted cash at the beginning of the period	67,119	130,101
Cash and cash equivalents and restricted cash at the end of the period	47,164	77,999
Supplemental disclosure of cash flow information
Cash paid for income taxes	0	0
Cash paid for interest	756	0
Supplemental disclosure of noncash investing and financing activities
Deferred offering costs in accrued expenses and other current liabilities	$ 78	$ 0